levodopa has been researched along with pirenzepine in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (14.29) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 9 (64.29) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carrupt, PA; Crivori, P; Cruciani, G; Testa, B | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Debing, I; Ijzerman, AP; Vauquelin, G | 1 |
| Brianda, S; Delitala, G; Maioli, M; Mannelli, M; Pacifico, A; Palermo, M | 1 |
| Ghaemi, M; Rudolf, J; Schmülling, S | 1 |
| Factor, SA; Molho, ES | 1 |
| Minagar, A; Shulman, LM; Weiner, WJ | 1 |
| Ebinger, G; Izurieta-Sánchez, P; Michotte, Y; Sarre, S | 1 |
| Lees, AJ; Manson, AJ; Schrag, A | 1 |
| Fernandez, HH | 1 |
| Alvarez, M; Chacón, JR; Durán, E; Durán, JA | 1 |
| Gupta, N; Malhotra, P | 1 |
| Bai, O; Bowen, R; Chlan-Fourney, J; Keegan, D; Li, XM | 1 |
| Hoefnagels, WH; Horstink, MW; Scheepmaker, AJ; Strijks, FE | 1 |
2 trial(s) available for levodopa and pirenzepine
| Article | Year |
|---|---|
Low-dose olanzapine for levodopa induced dyskinesias.
Topics: Aged; Benzodiazepines; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Olanzapine; Pirenzepine | 2000 |
[Usefulness of olanzapine in the levodopa-induced psychosis in patients with Parkinson's disease].
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Antipsychotic Agents; Benzodiazepines; Female; Humans; Levodopa; Male; Middle Aged; Olanzapine; Parkinson Disease; Pirenzepine; Prospective Studies; Psychoses, Substance-Induced | 2002 |
12 other study(ies) available for levodopa and pirenzepine
| Article | Year |
|---|---|
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
Topics: Blood-Brain Barrier; Databases, Factual; Models, Chemical; Molecular Conformation; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Melanosome binding and oxidation-reduction properties of synthetic L-dopa-melanin as in vitro tests for drug toxicity.
Topics: Animals; Cattle; Chloroquine; Chlorpromazine; Electron Transport; Kinetics; Levodopa; Melanins; Melanocytes; NAD; Oxidation-Reduction; Pirenzepine | 1988 |
Cholinergic receptor control mechanisms for L-dopa, apomorphine, and clonidine-induced growth hormone secretion in man.
Topics: Adult; Apomorphine; Benzodiazepinones; Clonidine; Growth Hormone; Humans; Kinetics; Levodopa; Male; Parasympatholytics; Pirenzepine; Prolactin; Receptors, Cholinergic | 1983 |
Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Drug Therapy, Combination; Hallucinations; Humans; Levodopa; Male; Olanzapine; Paranoid Disorders; Parkinson Disease; Piperidines; Pirenzepine; Selegiline; Severity of Illness Index | 1999 |
Worsening of motor features of parkinsonism with olanzapine.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Antipsychotic Agents; Benzodiazepines; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Olanzapine; Parkinson Disease; Parkinson Disease, Secondary; Pirenzepine; Psychoses, Substance-Induced; Risk Factors | 1999 |
Quetiapine for l-dopa-induced psychosis in PD.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Humans; Levodopa; Male; Olanzapine; Parkinson Disease; Pirenzepine; Psychoses, Substance-Induced; Quetiapine Fumarate; Treatment Outcome | 2000 |
Muscarinic antagonists in substantia nigra influence the decarboxylation of L-dopa in striatum.
Topics: Analysis of Variance; Animals; Corpus Striatum; Decarboxylation; Diamines; Dopamine; Extracellular Space; gamma-Aminobutyric Acid; Levodopa; Male; Microdialysis; Muscarinic Antagonists; Neurotransmitter Agents; Parasympatholytics; Perfusion; Pirenzepine; Rats; Rats, Wistar; Receptor, Muscarinic M1; Receptor, Muscarinic M2; Receptors, Muscarinic; Substantia Nigra; Time Factors; Trihexyphenidyl | 2000 |
Quetiapine for l-dopa-induced psychosis in PD.
Topics: Antipsychotic Agents; Dibenzothiazepines; Humans; Levodopa; Parkinson Disease; Pirenzepine; Psychoses, Substance-Induced | 2000 |
Olanzapine: a proarrhythmic drug?
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Benzodiazepines; Carbidopa; Electrocardiography; Female; Humans; Levodopa; Long QT Syndrome; Olanzapine; Pirenzepine; Psychoses, Substance-Induced; Risk Factors | 2002 |
Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Benzodiazepines; Brain-Derived Neurotrophic Factor; Clozapine; Dopamine Agents; Dose-Response Relationship, Drug; Gene Expression; Haloperidol; Hippocampus; In Situ Hybridization; Levodopa; Male; Olanzapine; Pirenzepine; Rats; Rats, Wistar; RNA, Messenger | 2003 |
[Dementia with Lewy bodies; 2 patients with exacerbation due to an atypical antipsychotic, but with a favorable response to the cholinesterase inhibitor rivastigmine].
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Antipsychotic Agents; Benzodiazepines; Carbamates; Cholinesterase Inhibitors; Drug Therapy, Combination; Humans; Levodopa; Lewy Body Disease; Male; Neuroprotective Agents; Olanzapine; Phenylcarbamates; Pirenzepine; Risperidone; Rivastigmine; Treatment Outcome | 2003 |